Palvella Q3: $236.7M Cash, Net Loss Widens to $24.6M Ahead of Feb 28, 2027 PDUFA
PVLA has more than doubled off its 52-week low of $71.55 on elevated volume (1.8× avg).
Summary
Palvella reported a Q3 2026 net loss of $24.6 million with $236.7 million in cash as of September 30, enough to fund the planned 1H 2027 launch while the FDA reviews QTORIN rapamycin ahead of a February 28, 2027 PDUFA date.
Key Events · Earnings and Guidance · PVLA
-
Q3 Net Loss Widens to $24.6M
Net loss was $24.6 million, or $1.70 per basic and diluted share, versus $11.3 million, or $1.03, a year earlier, driven by R&D of $10.8 million and G&A of $11.9 million.
-
Cash of $236.7M Funds Launch
Cash, cash equivalents and short-term investments totaled $236.7 million as of September 30, 2026, funding the planned standalone U.S. launch in the first half of 2027.
-
PDUFA Date February 28, 2027
The FDA accepted the QTORIN rapamycin NDA for microcystic lymphatic malformations with Priority Review and a February 28, 2027 target action date, as previously disclosed on October 28.
-
CMO Hire Effective December 21
James R. Treat, M.D., a pediatric dermatologist and prior SELVA investigator, joins as Chief Medical Officer effective December 21, 2026.
Analysis · PVLA · Life Sciences
The quarter's cash burn is the real news: net loss widened to $24.6 million from $11.3 million a year ago as R&D ($10.8M) and G&A ($11.9M) scaled for a commercial launch. Against $236.7 million of cash and short-term investments at September 30, that burn still funds the standalone U.S. launch planned for the first half of 2027 and the February 28, 2027 PDUFA date for QTORIN rapamycin in microcystic lymphatic malformations, so no financing appears imminent. The regulatory headline was already public on October 28; what is new is the spending trajectory, the CMO hire effective December 21, 2026, and market research pointing to strong prescribing intent and payer coverage.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PVLA was trading at $153.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $71.55 to $163.75. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.